UAE – M42’s Group CEO, Hasan Jasem Al Nowais, vows to globalize Abu Dhabi’s Health Innovations after historic Telerobotic procedure during the Abu Dhabi Global Health Week.
The landmark event streamed live from Abu Dhabi, showcased a simulated patient in South Korea undergoing a remote procedure, demonstrating the technology’s potential in interventional procedures like stroke and cardiovascular emergencies.
Al Nowais, speaking as the inaugural Abu Dhabi Global Healthcare Week 2024 (ADGHW) drew to a close, emphasized M42’s pivotal role as the official Foundation Partner of the event.
“We would like to pioneer this [technology] here, working closely with XCath and take this from Abu Dhabi to the world,” he stated, underlining M42’s commitment to leveraging technology for transformative healthcare solutions.
Following the demonstration, Al Nowais highlighted plans to trial remote blood clot removal technology at Cleveland Clinic Abu Dhabi, designated as a Center of Excellence for stroke care by the Department of Health – Abu Dhabi (DoH).
He emphasized M42’s strategy to drive global health transformations through technological advancements.
Reflecting on ADGHW, Al Nowais remarked, “Abu Dhabi Global Healthcare Week surpassed all our expectations, offering a platform for M42 to engage with international leaders and showcase the latest advancements in health.”
He reiterated M42’s focus on prioritizing people, health, and prevention alongside strategic investments and partnerships to deliver world-class healthcare solutions powered by AI and innovative technologies.
Throughout the event, hosted by DoH under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of Abu Dhabi Executive Council, M42 introduced several initiatives to revolutionize health through technology and partnerships.
These initiatives included launching the region’s largest hybrid cord blood bank and signing four MoUs for comprehensive preventive, precise, and personalized healthcare solutions.
M42 also unveiled Med42, a Next-Generation Clinical large language model (LLM), aligning with global tech leaders to advance health-tech innovations.
The announcement of M42’s Advisory Board, comprising world-renowned health and technology experts, enhanced the company’s commitment to driving innovation in the sector.
M42’s Main Stage hosted thought-provoking discussions and major announcements, collaborating with the Longevity Forum to explore the intersection of health, technology, and sustainability.
Al Nowais emphasized the importance of partnerships in advancing global health, outlining a three-pronged approach for greater access and adaptation.
Dr. James Mault, CEO of BioIntellisense and Advisory Board member, highlighted M42’s unique genomics and AI care offerings, positioning M42 at the forefront of care advancement.
He emphasized the Board’s diverse expertise in translating innovations into tangible outcomes.
In addition, panel discussions highlighted AI’s transformative potential in personalized health and precision care.
Experts envisioned a future where aging is treated as a medical condition, emphasizing AI’s role in driving innovation and sustainability.
Engaging with US and UK Trade Delegations, M42 showcased its extensive network and pioneering digital health solutions.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook
